mSphere
(Jun 2021)
Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures
L. C. Rijsbergen,
M. M. Lamers,
A. D. Comvalius,
R. W. Koutstaal,
D. Schipper,
W. P. Duprex,
B. L. Haagmans,
R. D. de Vries,
R. L. de Swart
Affiliations
L. C. Rijsbergen
Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
M. M. Lamers
Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
A. D. Comvalius
Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
R. W. Koutstaal
Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
D. Schipper
W. P. Duprex
ORCiD Center for Vaccine Research, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
B. L. Haagmans
ORCiD Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
R. D. de Vries
ORCiD Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
R. L. de Swart
ORCiD Department of Viroscience, Postgraduate School of Molecular Medicine, Erasmus MC, Rotterdam, the Netherlands
DOI
https://doi.org/10.1128/mSphere.00237-21
Journal volume & issue
Vol. 6,
no. 3
Abstract
Read online
Human respiratory syncytial virus (HRSV) is the major cause of bronchiolitis and pneumonia in young infants and causes almost 200,000 deaths per year. Currently, there is no vaccine or treatment available, only a prophylactic monoclonal antibody (palivizumab).
WeChat QR code
Close
